BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
insight
/
details

Breaking Ground in Neuroblastoma Treatment: From Anti-GD2 Antibodies to Precision Medicine

NextEdge Admin

16 Apr 2024

2 min 23 sec

Precision Medicine,CAR-T therapy,Research

Neuroblastoma, the most common extracranial solid cancer in childhood, arises primarily in the adrenal glands or nerve tissue along the spine, chest, abdomen, or pelvis. Standard treatments, including induction chemotherapy, surgery, and immunotherapy, have only modestly improved outcomes, with over 50% of high-risk patients experiencing resistance or relapse, leading to dismal survival rates. This underscores the critical need for novel agents in the treatment of neuroblastoma.

Targeted therapies, especially Anti-GD2 antibodies like dinutuximab and naxitamab, have shown promise in specifically binding to neuroblastoma cells. The glycolipid GD2, overexpressed on these cancer cells, becomes a target for these monoclonal antibodies. Dinutuximab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

While CAR-T therapy for neuroblastoma is in its early stages, challenges such as target selection, antibody site screening, and optimizing CAR structure persist.

Research efforts also focus on therapies targeting actionable mutations and aberrantly activated signaling pathways in recurrent neuroblastoma. Despite preclinical promise, early-phase clinical trials have often yielded disappointing results, emphasizing the need for a deeper understanding of molecular biology in relapse and resistance mechanisms.

Early identification of high-risk patients is crucial for intervention with novel agents, and the emphasis on precision medicine reflects a broader trend towards personalized and targeted approaches in neuroblastoma treatment, offering hope for improved prognosis and survival rates.